论文部分内容阅读
目的分析云克联合~(89)Sr治疗骨转移癌的临床案例,为该疾病的临床治疗提供可靠依据。方法将我院接受诊治的62例骨转移癌患者(88处骨转移)作为研究对象,随机均分为两组,观察组采用云克联合~(89)Sr治疗,对照组采用全身放射治疗,对比两组的疼痛改善效果及不良反应情况。结果观察组的疼痛改善率为93.56%,明显高于对照组的74.19%,差异显著(P<0.05);且观察组骨髓抑制、肝肾功能受损及胃肠道不良反应发生率均显著低于对照组,差异显著(P<0.05)。结论 ECT联合X线在骨转移癌的临床诊断准确率高,云克联合~(89)Sr治疗骨转移癌,可有效改善患者骨痛症状,提高治疗效果。
Objective To analyze the clinical application of Yunke combined with (89) Sr in the treatment of bone metastases and provide a reliable basis for the clinical treatment of this disease. Methods Totally 62 patients with bone metastatic carcinoma (88 bone metastases) undergoing treatment in our hospital were randomly divided into two groups. The observation group was treated with Yunke combined with (89) Sr, the control group with systemic radiotherapy, Compare the two groups of pain to improve the effect and adverse reactions. Results The improvement rate of pain in the observation group was 93.56%, which was significantly higher than that in the control group (74.19%) (P <0.05). And the incidence of bone marrow suppression, liver and kidney dysfunction and gastrointestinal adverse reactions in the observation group were significantly lower In the control group, the difference was significant (P <0.05). Conclusion The accuracy of ECT combined with X-ray in the diagnosis of bone metastases is high. Yunke combined with 89 Sr treatment of bone metastases can effectively improve the symptoms of bone pain and improve the therapeutic effect.